nach oben

21.08.2019 | Original Article

Population frequencies of pathogenic alleles of BRCA1 and BRCA2: analysis of 173 Danish breast cancer pedigrees using the BOADICEA model

verfasst von: Thorkild Terkelsen, Lise-Lotte Christensen, Deirdre Cronin Fenton, Uffe Birk Jensen, Lone Sunde, Mads Thomassen, Anne-Bine Skytte

Erschienen in: Familial Cancer | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) calculates the probability that a woman carries a pathogenic variant in BRCA1 or BRCA2 based on her pedigree and the population frequencies of pathogenic alleles of BRCA1 (0.0006394) and BRCA2 (0.00102) in the United Kingdom (UK). BOADICEA allows the clinician to define the population frequencies of pathogenic alleles of BRCA1 and BRCA2 for other populations but only includes preset values for the Ashkenazy Jewish and Icelandic populations. Among 173 early-onset breast cancer pedigrees in Denmark, BOADICEA discriminated well between carriers and non-carriers of pathogenic variants (area under the receiver operating characteristics curve: 0.81; 95% CI 0.74–0.86) but underestimated the frequency of carriers of pathogenic variants in BRCA1 or BRCA2 as measured by the observed-to-expected ratio (O/E 1.83; 95% CI 1.18–2.84). This reflects findings from older studies of BOADICEA in UK, German, Italian, and Chinese populations, all accounting for the different calibration for different carrier probabilities. To improve the performance of BOADICEA for non-UK populations, we developed a method to derive population frequencies of pathogenic alleles of BRCA1 and BRCA2. Compared to the UK population frequencies, we estimated the Danish population frequencies of pathogenic alleles to be higher for BRCA1 (0.0015; 95% CI 0.00064–0.0034) and lower for BRCA2 (0.00052; 95% CI 0.00018–0.0017) after adjusting for the different calibration of BOADICEA for different carrier probabilities. Incorporating additional population frequencies into BOADICEA could improve its performance for non-UK populations.

Nur mit Berechtigung zugänglich

Peto J, Collins N, Barfoot R et al (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91(11):943–949CrossRefPubMed

Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A (2001) Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst 93(16):1215–1223CrossRefPubMed

Fackenthal JD, Olopade OI (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 7(12):937–948. https://doi.org/10.1038/nrc2054 CrossRefPubMed

Cintolo-Gonzalez JA, Braun D, Blackford AL et al (2017) Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications. Breast Cancer Res Treat 164(2):263–284. https://doi.org/10.1007/s10549-017-4247-z CrossRefPubMed

Bredart A, Kop JL, Antoniou AC et al (2018) Use of the BOADICEA web application in clinical practice: appraisals by clinicians from various countries. Fam Cancer 17(1):31–41. https://doi.org/10.1007/s10689-017-0014-x CrossRefPubMed

Lee AJ, Cunningham AP, Kuchenbaecker KB et al (2014) BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Br J Cancer 110(2):535–545. https://doi.org/10.1038/bjc.2013.730 CrossRefPubMed

Antoniou AC, Hardy R, Walker L et al (2008) Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet 45(7):425–431. https://doi.org/10.1136/jmg.2007.056556 CrossRefPubMed

Fischer C, Kuchenbacker K, Engel C et al (2013) Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium. J Med Genet 50(6):360–367. https://doi.org/10.1136/jmedgenet-2012-101415 CrossRefPubMed

Stahlbom AK, Johansson H, Liljegren A, von Wachenfeldt A, Arver B (2012) Evaluation of the BOADICEA risk assessment model in women with a family history of breast cancer. Fam Cancer 11(1):33–40. https://doi.org/10.1007/s10689-011-9495-1 CrossRefPubMed

10.

Varesco L, Viassolo V, Viel A et al (2013) Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: a retrospective study in a sample of Italian cancer genetics clinics. Breast 22(6):1130–1135. https://doi.org/10.1016/j.breast.2013.07.053 CrossRefPubMed

11.

Antoniou AC, Durocher F, Smith P, Simard J, Easton DF, members IBp (2006) BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Res 8(1):R3. https://doi.org/10.1186/bcr1365 CrossRefPubMed

12.

Kurian AW, Gong GD, John EM et al (2009) Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry. Cancer Epidemiol Biomark Prev 18(4):1084–1091. https://doi.org/10.1158/1055-9965.EPI-08-1090 CrossRef

13.

Thirthagiri E, Lee SY, Kang P et al (2008) Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer. Breast Cancer Res 10(4):R59. https://doi.org/10.1186/bcr2118 CrossRefPubMedPubMedCentral

14.

Kwong A, Wong CH, Suen DT et al (2012) Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort. World J Surg 36(4):702–713. https://doi.org/10.1007/s00268-011-1406-y CrossRefPubMedPubMedCentral

15.

Antoniou AC, Cunningham AP, Peto J et al (2008) The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 98(8):1457–1466. https://doi.org/10.1038/sj.bjc.6604305 CrossRefPubMedPubMedCentral

16.

Gerdes AM, Cruger DG, Thomassen M, Kruse TA (2006) Evaluation of two different models to predict BRCA1 and BRCA2 mutations in a cohort of Danish hereditary breast and/or ovarian cancer families. Clin Genet 69(2):171–178. https://doi.org/10.1111/j.1399-0004.2006.00568.x CrossRefPubMed

17.

Pedersen IS, Schmidt AY, Bertelsen B et al (2018) A Danish national effort of BRCA1/2 variant classification. Acta Oncol 57(1):159–162. https://doi.org/10.1080/0284186X.2017.1400693 CrossRefPubMed

18.

Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR (2005) Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 123(1):21–27CrossRefPubMed

19.

Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA (2001) Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 93(5):358–366CrossRefPubMed

20.

DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3):837–845CrossRefPubMed

21.

Manchanda R, Legood R, Burnell M et al (2015) Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing. J Natl Cancer Inst 107(1):380. https://doi.org/10.1093/jnci/dju380 CrossRefPubMed

22.

Copson ER, Maishman TC, Tapper WJ et al (2018) Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol 19(2):169–180. https://doi.org/10.1016/S1470-2045(17)30891-4 CrossRefPubMedPubMedCentral

23.

Ford D, Easton DF, Peto J (1995) Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57(6):1457–1462PubMedPubMedCentral

24.

Jervis S, Song H, Lee A et al (2015) A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects. J Med Genet 52(7):465–475. https://doi.org/10.1136/jmedgenet-2015-103077 CrossRefPubMed

25.

Lilyquist J, LaDuca H, Polley E et al (2017) Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. Gynecol Oncol 147(2):375–380. https://doi.org/10.1016/j.ygyno.2017.08.030 CrossRefPubMedPubMedCentral

26.

Rebbeck TR, Friebel TM, Friedman E et al (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39(5):593–620. https://doi.org/10.1002/humu.23406 CrossRefPubMedPubMedCentral

27.

Rebbeck TR, Mitra N, Wan F et al (2015) Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313(13):1347–1361. https://doi.org/10.1001/jama.2014.5985 CrossRefPubMedPubMedCentral

28.

Byers H, Wallis Y, van Veen EM et al (2016) Sensitivity of BRCA1/2 testing in high-risk breast/ovarian/male breast cancer families: little contribution of comprehensive RNA/NGS panel testing. Eur J Hum Genet 24(11):1591–1597. https://doi.org/10.1038/ejhg.2016.57 CrossRefPubMedPubMedCentral

Titel: Population frequencies of pathogenic alleles of BRCA1 and BRCA2: analysis of 173 Danish breast cancer pedigrees using the BOADICEA model
verfasst von: Thorkild Terkelsen
Lise-Lotte Christensen
Deirdre Cronin Fenton
Uffe Birk Jensen
Lone Sunde
Mads Thomassen
Anne-Bine Skytte
Publikationsdatum: 21.08.2019
Verlag: Springer Netherlands
Erschienen in: Familial Cancer / Ausgabe 4/2019
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-019-00141-9

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Population frequencies of pathogenic alleles of BRCA1 and BRCA2: analysis of 173 Danish breast cancer pedigrees using the BOADICEA model

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie